About CBD

What is CBD and CBG?

CBD and CBG are derived from industrial hemp. Industrial hemp has an incredible picture all around the world. Medical industry enormously uses the advantages of this plant for relieving various ailments. It contains certain powerful compounds known as cannabinoids which interact with the body through the Endocannabinoid System. In the hemp plant, there are many different cannabinoids present, from which the two popular cannabinoids, CBD (Cannabidiol) and CBG (Cannabigerol) will be explained in detail below. 

CBD (cannabidiol)

The essential element of CBD is that it is nonpsychoactive cannabinoid. CBD effectively eliminates the toxic impacts of THC like drowsiness, memory impairment, intoxication and getting high. It is a critical compound as CBD oil contains vitamins and minerals to boost the everyday schedule of a person. CBD has extraordinary dietary value. It also contains Omega 6 and Omega 3 polyunsaturated unsaturated fats, vitamin E, C, B1, B2, B3, and B6. That is the reason CBD has considerable nutritional worth around the globe (Conrad, 1997).

Why is CBD effective

The endocannabinoid system has an overwhelming role with CBD. It joins with the cannabinoid receptors in various regions of the body primarily in the Central nervous system by the antipsychotic impact  (Tokes, 2016). It comprises of extensive medical benefits, and CBD is also very easy to utilize. It is generally used in different forms and people can utilize it as according to their need. As CBD is a nonpsychoactive compound, it helps to eradicate psychoactive effects induced by the other compounds found in the cannabis plant.

CBD Uses

CBD is greatly utilized by the medical industry. CBD is gaining popularity day by day due to its broad medical benefits. Some of the uses of CBD in medical disorders are as follows:

Psychotic Disorders


A transitional report of around thirty years claimed that CBD help in psychotic problems, for instance, schizophrenia issue (Zuardi, Crippa, Hallak, Bhattacharyya, & Atakan, 2012)



CBD is prescribed to eliminate the indications of a wide range of cancers and tumors  (Burstein, 2015).



Regarding the viability of CBD in diabetes, some examinations were conducted that finished with positive results (Weiss, Zeira, Reich, Slavin, & Raz, 2008).


 A receptor (5-HT1A) consolidates CBD induced antidepressant effect and raise levels of glutamate that is the reason CBD is known to be a fast-acting antidepressant (Linge, Jim{\'e}nez-S{\'a}nchez, Campa, Pilar-Cu{\'e}llar, & Vidal, 2016). It helps mitigate depression in some people.


CBG is the parent compound of THC and CBD it may also be said that THC and CBD begin out as CBG. It is a crucial cannabinoid which has nonpsychoactive effects on the human body which makes it very easy to consume without any side effects. Since it is available in less quantity (1% or less) in many cannabis strains, CBG is considered a minor cannabinoid. A few examinations have expressed that CBG is found in higher rates in hemp plants than in cannabis, perhaps on the grounds that they were reproduced to not break into the active cannabinoids like THC and CBD.

Why is CBG effective

CBG communicates with both the CB1 and CB2 receptors, acting as a potential inhibitor to the psychoactive effects of THC. CBG is additionally thought to enhance anandamide, an endocannabinoid which naturally raises the level of dopamine and in charge of managing different health functions for example appetite, mood, and sleeps. GABA uptake in the brain might be hindered by CBG, making CBG a potential anti-anxiety agent also the muscle relaxant. This cannabinoid may also block serotonin receptors, demonstrating possible antidepressant traits.

CBG Uses

CBG is an important compound which has various medical uses. Due to its extensive uses, CBG is being very popular around the world. Some of the uses are as follows:


CBG is very effective against Methicillin-Resistant Staphylococcus Aureus (MRSA)  (Appendino, et al., 2008)

Psoriasis Treatment

It possesses Antiproliferative effects on the human body and is greatly effective for skin diseases predominantly for psoriasis. CBG also prevents redness of skin (Wilkinson & Williamson, 2007)


CBG also possess antidepressant functions to raise the level of serotonin in the human brain (Pertwee, 2008)


A study conducted on mouse skin termed CBG as the anti-tumor (Baek, Du Han, Yook, Kim, & Kwak, 1996). It has been effective in treating oral cancers in human primarily oral epitheloid carcinoma cells (Baek, Kim, Kwag, Choi, & Jung, 1998)


CBG like other cannabinoids is effective against pain but is more efficient than THC (Russo, 2008).

 Are CBD and CBG safe?

In the USA, The Drug Awareness Warning Network Annual Report was presented which is explained by the Substance Abuse and Mental Health Services Administration and according to this up till now no death has been observed by the use of cannabis  (Centers for Disease Control and Prevention, 2017). It has been observed as completely safe for human. The broad medical uses of cannabis and cannabinoid are not denied around the globe.

It is evident from the above discussion that CBD and CBG are of great importance as they are very helpful for people without any side effects. They not only have therapeutic potential for the above mentioned diseases but they can be also used as nutritional supplements as they are of great dietary value. Scientists are very supportive of these compounds which is why they are not only focused on furthering research but also increasing production of cannabinoids. 

Understanding the Endocannabinoid System (ECS) …

The ECS is in charge of multiple tasks. Main goal being to maintain a stable environment despite fluctuations in the external environment. It is responsible for homeostasis within the body. Homeostasis is the maintaining of metabolic equilibrium within our bodies. When an imbalance is detected internally, we synthesize endocannabinoids that interact with the cannabinoid receptors. Stimulating a chemical response enabling us to return back to homeostasis.

First discovery of Endocannabinoids …

The first Endocannabinoid., Anandamide was discovered in 1992. Thus it wasn’t till recently we began to explore the hidden potential of the ECS. This also explains why most current doctors are not always familiar with the ECS and its medicinal potential.

Recent science has discovered that the ECS responds to more than just the endocannabinoids produced in the body, but also to external cannabinoids such as CBD and CBG.

CBD and CBG are BOTH non-psychoactive Cannabinoids derived from Hemp. The synergy between the two enhance the medicinal effects through what is known as the entourage effect.

Why would one want to supplement with Cannabinoids?

In some cases, there is a deficiency in Endocannabinoid System signaling. This condition is known as Clinical Endocannabinoid Deficiency. Explanations for this deficiency ranges from…

  • our body not synthesizing enough endocannabinoids
  • our bodies not producing enough cannabinoid receptors
  • an abundance of enzymes that break down cannabinoids
  • or outside sources such as foods and medications that decrease ECS signaling.

Research suggests one can supplement this deficiency through cannabinoids such as CBD and CBG. Scientists believe your ECS may have the potential to relieve a multitude of illnesses and conditions from anxiety to inflammation.

*The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. 


Appendino, Giovanni, Simon Gibbons, Anna Giana, Alberto Pagani, Gianpaolo Grassi, and Michael Stavri. "Antibacterial cannabinoids from Cannabis sativa: a structure- activity study." J. Nat. Prod (ACS Publications) 71, no. 8 (2008): 1427-1430.

Baek, Seung Hwa, Young Ok Kim, Jung Suk Kwag, Kyw Eun Choi, and Woo Young Jung. "Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells." Archives of pharmacal research (Springer) 21, no. 3 (1998): 353.

Baek, Seung-Hwa, Seok Du Han, Chan Nam Yook, Young Chae Kim, and Jung Suk Kwak. "Synthesis and antitumor activity of cannabigerol." Archives of Pharmacal Research (Springer) 19, no. 3 (1996): 228-230.

Burstein, Sumne. "Cannabidiol (CBD) and its analogs: a review of their effects on inflammation." Bioorganic \& medicinal chemistry (Elsevier) 23, no. 7 (2015): 1377-1385.

Centers for Disease Control and Prevention. National Estimates of Marijuana Use and Related Indicators — National Survey on Drug Use and Health, United States, 2002–2014. June 21, 2017. https://www.cdc.gov/mmwr/volumes/65/ss/ss6511a1.htm?s_cid=ss6511a1_w.

Conrad, Chris. Hemp for health: The medicinal and nutritional uses of Cannabis sativa. Rochester, Vermont: Inner Traditions/Bear \& Co, 1997.

Devinsky, Orrin, et al. "Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders." Epilepsia (Wiley Online Library) 55, no. 6 (2014): 791-802.

Linge, Raquel, Laura Jim{\'e}nez-S{\'a}nchez, Leticia Campa, Fuencisla Pilar-Cu{\'e}llar, and Rebeca Vidal. "Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT 1A receptors." Neuropharmacology (Elsevier) 103 (2016): 16-26.

Mechoulam, Raphael, Maximilian Peters, Eric Murillo-Rodriguez, and Lum{\'\i}r O Hanu{\v{s}}. "Cannabidiol--recent advances." Chemistry \& biodiversity (Wiley Online Library) 4, no. 8 (2007): 1678-1692.

Pertwee, Roger. "Therapeutic uses of cannabigerol." Google Patents, June 25, 2008.

Russo, Ethan B. "Cannabinoids in the management of difficult to treat pain." Therapeutics and Clinical Risk Management (Dove Press) 4, no. 1 (2008): 245.

Tokes, Ray. What is CBD - The Truth about Cannabidiol - Medication. 2016.

Weiss, Lola, Michael Zeira, Shoshana Reich, Shimon Slavin, and Itamar Raz. "Cannabidiol arrests onset of autoimmune diabetes in NOD mice." Neuropharmacology (Elsevier) 54, no. 1 (2008): 244-249.

Wilkinson, Jonathan D, and Elizabeth M Williamson. "Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis." Journal of dermatological science (Elsevier) 45, no. 2 (2007): 87-92.

Zuardi, Antonio Waldo, J Alexandre Crippa, JE Hallak, Sagnik Bhattacharyya, and Zerrin Atakan. "A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation." Curr Pharm Des 18, no. 32 (2012): 5131-40.